CeNeRx BioPharma Announces Successful Completion Of Phase L Clinical Program For Novel Antidepressant Agent Tyrima(TM)
Jan 29th 2008Drug InformationDepression
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, announced the successful completion of the Phase l clinical program for Tyrima(TM), its lead candidate for the treatment of depression and anxiety. Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
